JP2022520871A5 - - Google Patents
Info
- Publication number
- JP2022520871A5 JP2022520871A5 JP2021548697A JP2021548697A JP2022520871A5 JP 2022520871 A5 JP2022520871 A5 JP 2022520871A5 JP 2021548697 A JP2021548697 A JP 2021548697A JP 2021548697 A JP2021548697 A JP 2021548697A JP 2022520871 A5 JP2022520871 A5 JP 2022520871A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- mil
- population
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808031P | 2019-02-20 | 2019-02-20 | |
| US62/808,031 | 2019-02-20 | ||
| PCT/US2020/018897 WO2020172328A1 (en) | 2019-02-20 | 2020-02-19 | Expansion of natural killer and chimeric antigen receptor-modified cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520871A JP2022520871A (ja) | 2022-04-01 |
| JP2022520871A5 true JP2022520871A5 (enExample) | 2023-02-10 |
| JP7575104B2 JP7575104B2 (ja) | 2024-10-29 |
Family
ID=72143864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548697A Active JP7575104B2 (ja) | 2019-02-20 | 2020-02-19 | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12453773B2 (enExample) |
| EP (1) | EP3927730A4 (enExample) |
| JP (1) | JP7575104B2 (enExample) |
| CN (1) | CN113710691B (enExample) |
| CA (1) | CA3131879A1 (enExample) |
| WO (1) | WO2020172328A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| US20240285791A1 (en) * | 2020-09-04 | 2024-08-29 | Daegu Gyeongbuk Institute Of Science And Technology | Extracellular vesicle expressing cytokine and antibody, method for producing same, and use thereof |
| WO2023182801A1 (ko) * | 2022-03-24 | 2023-09-28 | (주) 테라베스트 | 자연살해세포를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
| TWI877602B (zh) * | 2022-04-21 | 2025-03-21 | 中央研究院 | 用於延長壽命及／或治療癌症的經基因工程化先天淋巴細胞 |
| CN114736859B (zh) * | 2022-06-13 | 2022-08-19 | 广东先康达生物科技有限公司 | 一种脐带血nk细胞的培养液及培养方法 |
| CN116254230A (zh) * | 2022-09-14 | 2023-06-13 | 卡瑞济(北京)生命科技有限公司 | 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途 |
| CN115612673A (zh) * | 2022-12-14 | 2023-01-17 | 卡瑞济(北京)生命科技有限公司 | 一种改善car-t细胞群的持久性的方法 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
| CN121889492A (zh) * | 2023-07-21 | 2026-04-17 | 盖亚生物制药有限公司 | 细胞群的制备方法 |
| CN117187181B (zh) * | 2023-11-08 | 2024-03-19 | 普华赛尔生物医疗科技有限公司 | 包被组合物的方法及其应用 |
| WO2025178407A1 (ko) * | 2024-02-23 | 2025-08-28 | 마루테라퓨틱스 주식회사 | 고효율 유도 자연살해세포(ink) 증식 방법 |
| WO2025251226A1 (en) * | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005127B2 (en) * | 2002-03-29 | 2006-02-28 | Tissuegene, Inc. | Mixed-cell gene therapy |
| CN102559600A (zh) * | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| WO2015154012A1 (en) | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| RU2739770C2 (ru) | 2014-06-11 | 2020-12-28 | полибайосепт ГмбХ | Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии |
| JP7086928B2 (ja) | 2016-07-25 | 2022-06-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| AU2017347854B2 (en) | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
| CA3056591A1 (en) * | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
-
2020
- 2020-02-19 EP EP20758646.2A patent/EP3927730A4/en active Pending
- 2020-02-19 US US17/432,380 patent/US12453773B2/en active Active
- 2020-02-19 CN CN202080029826.4A patent/CN113710691B/zh active Active
- 2020-02-19 CA CA3131879A patent/CA3131879A1/en active Pending
- 2020-02-19 JP JP2021548697A patent/JP7575104B2/ja active Active
- 2020-02-19 WO PCT/US2020/018897 patent/WO2020172328A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520871A5 (enExample) | ||
| Engels et al. | Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes | |
| Bernareggi et al. | Development of innate immune cells from human pluripotent stem cells | |
| Dahlberg et al. | Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity | |
| Tonn et al. | Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 | |
| JP2021509287A (ja) | キメラ抗原受容体（ｃａｒ）またはトランスジェニックｔ細胞受容体（ｔｃｒ）の発現のためのウイルスベクターで細胞を形質導入するための方法 | |
| JP7391038B2 (ja) | Ｔｒｅｇ細胞の抑制特性を増強するための方法 | |
| JP2021514665A5 (enExample) | ||
| JP2024086827A5 (enExample) | ||
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| WO2020086989A1 (en) | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy | |
| WO2008071701A1 (en) | Expression of transgenic t cell receptors in lak-t cells | |
| JP2024524185A (ja) | 抗原特異的ｔ細胞を生成するための方法 | |
| WO2025255886A1 (zh) | 一种诱导性nk细胞及其制备方法和应用 | |
| US11788072B2 (en) | Activation of APC in immunotherapy | |
| CN111286486A (zh) | 体外大量扩增恶性肿瘤腹水浸润的淋巴细胞的方法 | |
| CN117402231B (zh) | 一种自发传递il-21信号的受体及其应用 | |
| US9205111B2 (en) | Process for producing engineered targeted T cell and medicine | |
| JP2022513584A (ja) | サイトカインを分泌するように改変されたｐｄｃ株 | |
| Han et al. | Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy | |
| Kühnel et al. | Engineered Natural Killer Cell Lines and Their Application for Cancer Immunotherapy | |
| US20250302958A1 (en) | Improved cell therapies | |
| JP7725014B2 (ja) | ＨＴＬＶ－１がコードするＴａｘ抗原特異的細胞傷害性Ｔリンパ球のＴ細胞受容体又はその機能的断片 | |
| JP7847359B2 (ja) | Ｎｋ細胞の培養方法 | |
| RU2786210C1 (ru) | Биомедицинский клеточный продукт со специфической противоопухолевой активностью, представленный популяциями лимфокин-активированных киллеров и анти-HER2 CAR-γδΤ-ОИЛ и анти-HER2 CAR-T-NK |